Metoclopramide and acepromazine interaction in dogs
Published: · Updated:
An official dog-and-cat metoclopramide label states that concurrent use with phenothiazine neuroleptics such as acepromazine increases the risk of extrapyramidal effects.
Summary references: [1]
What is the concern when a dog receives metoclopramide with acepromazine?
The Metomotyl product information warns of an increased risk of extrapyramidal effects when metoclopramide is used with phenothiazine neuroleptics such as acepromazine. Its adverse-reaction section describes effects involving movement, posture or behaviour. This warning does not establish the frequency for this particular combination. [1]
Mechanism and evidence interpretation
Additive extrapyramidal-effect risk. The source is a product-information warning for dogs and cats. It identifies a risk category and does not predict whether an individual dog will develop a specific sign. [1]
Concurrent use of metoclopramide with neuroleptics derived from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). [1]
Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). [2] [3]
The quotation is the recorded official-label wording. It may mention other medicines; only the pair in this article’s title is discussed here.
What should be checked before concurrent use?
These are questions for veterinary review, not instructions to start, stop or change a medicine.
- Check the metoclopramide formulation and route against the actual product information.
- Include sedatives and all other concurrent medicines in the veterinary review.
- Describe any observed changes in movement, posture or behaviour to the treating veterinarian. Product-label adverse-event frequencies must not be presented as incidence estimates for the drug pair.
Which animals and evidence types does this cover?
The selected catalogue scope is dogs. A product-label statement is not automatically a controlled interaction trial. It does not establish an effect size, incidence, dose adjustment or applicability to another species.
Is this merely a statement that both medicines cause sedation?
No. The cited interaction warning specifically concerns extrapyramidal effects. A separate statement about central nervous system depressants in a label should not be substituted for that pair-specific warning.
No matching rule does not establish safety. FDA adverse-event reports alone cannot prove an interaction or its incidence.
Catalogue review status and limitations
The matched catalogue records are marked verified and direct. This is a catalogue review status; it does not mean every patient-specific conclusion has been clinically demonstrated.
- Catalogue review status
- verified
- Inference status
- direct
- Stored interaction role
- risk_interaction
- Catalogue severity
- moderate
These fields are shown separately. They are not a claim of independent expert consensus or a patient-specific recommendation.
Evidence sources
This page draws on 3 catalogue record(s) and 3 distinct source entries. These are not independent clinical studies; repeated product labels may carry the same warning.
The summary was checked against the linked primary VMD PDF on 16 November 2026. Source URLs can change; the catalogue citations retain recorded version identifiers.
- Official product information
VMD PID:A008831, Metomotyl 5 mg/ml Solution for Injection for Cats and Dogs, version b33134733a18a6a44b42fddbfb805c4f Open official source
- Official product information
VMD PID:A007820, Emeprid 1 mg/ml Oral Solution for Dogs and Cats, version cf981f88566c484881bc6313c2dea313 Open official source
- Official product information
VMD PID:A007821, Emeprid 5 mg/ml Solution for Injection for Dogs and Cats, version ef1184581d2907f08852448a2ec86324 Open official source
Content responsibility: ZooDDI. This is a source-linked reference for veterinary review, not a diagnosis, prescription or emergency service. No independent clinical reviewer is claimed.